CN1646520A - 1,3,5-triazine derivatives as ligands for human adenosine-A3 receptors - Google Patents

1,3,5-triazine derivatives as ligands for human adenosine-A3 receptors Download PDF

Info

Publication number
CN1646520A
CN1646520A CNA038090937A CN03809093A CN1646520A CN 1646520 A CN1646520 A CN 1646520A CN A038090937 A CNA038090937 A CN A038090937A CN 03809093 A CN03809093 A CN 03809093A CN 1646520 A CN1646520 A CN 1646520A
Authority
CN
China
Prior art keywords
alkyl
general formula
group
compound
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA038090937A
Other languages
Chinese (zh)
Other versions
CN1329388C (en
Inventor
J·A·J·丹哈托格
J·H·赖德尔斯
G·J·M·万希勒伯格
M·L·普拉斯－雷弗斯
G·R·古斯塔弗森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Arqule Inc
Original Assignee
Solvay Pharmaceuticals GmbH
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals GmbH, Arqule Inc filed Critical Solvay Pharmaceuticals GmbH
Publication of CN1646520A publication Critical patent/CN1646520A/en
Application granted granted Critical
Publication of CN1329388C publication Critical patent/CN1329388C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/50—Two nitrogen atoms with a halogen atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)

Abstract

The invention relates to a group of novel triazine derivatives which are ligands for human adenosine-A3 receptors, as well as to pharmaceutical compositions containing a pharmacologically active amount of at least one of these compounds as an active ingredient. The invention relates to compounds of the general formula (1) wherein Y represents a group of the general formula (A), (B) or (C) and all other symbols have the meanings as given in the description.

Description

As people adenosine-A 3The novel 1,3,5-triazines derivative of receptors ligand
The present invention relates to one group of new pyrrolotriazine derivatives, it is people adenosine-A 3The part of acceptor.The invention still further relates at least a pharmaceutical composition in these new pyrrolotriazine derivatives that contain pharmacological activity amount as active ingredient.
Two kinds of well-known natural compounds caffeines and theophylline are brought into play its pharmacological activity by interacting with Adenosine Receptors.Research produces a very large impact to Adenosine Receptors in this discovery.At present, differentiated four class Adenosine Receptorss, and they have been appointed as A respectively 1, A 2A, A 2BAnd A 3All these four classes Adenosine Receptorss all belong to seven superfamilies of striding film G-protein linked receptor.Adenosine Receptors is ubiquitous, and relates to many kinds of bioprocesss.Therefore, in the many decades in the past, the treatment potentiality of adenosine receptor ligands cause the research interest that people are very big.Nearest summary is: S.Hess, Recent advances in adenosine receptor antagonist research, Expert Opin.Ther.Patents, 11,1,547 1562,2001, and M.A.Jacobson, adenosine receptor agonists, Expert Opin.Ther.Patents, 12 (4), 489-501,2002.
The part of various Adenosine Receptorss is themes of a large amount of patent applications and patent.In these patent applications and patent, have only in two pieces to disclose triaizine compounds.WO 991163 discloses a series of adenosine-A to the people that shown 12 of the nM level affinity of acceptor, the triazine that the 4-phenylbenzene replaces.
The patent application of second piece of open triaizine compounds is JP 11158073, and it is immediate prior art.This patent application discloses the 1,3,5-triazines of a series of replacement, and they are people adenosine-A 3The part of acceptor, wherein compounds effective has the affinity of about 15nM.
Surprisingly, have now found that in a series of pyrrolotriazine derivatives with the combination of new substituting group, one group of compound has shown to have adenosine-A to the people in low nM level scope 3The affinity of acceptor.
The present invention relates to the compound and the pharmacologically acceptable salt thereof of general formula (1),
Wherein
R 1The expression halogen, alkyl (1-3C), O-alkyl (1-3C), CF 3, NH 2, N-(two)-alkyl (1-3C), N-(two)-thiazolinyl (1-3C), N-(two)-alkynyl (1-3C), N-alkyl (1-3C) thiazolinyl (1-3C), N-alkyl (1-3C) alkynyl (1-3C), N-thiazolinyl (1-3C) alkynyl (1-3C) or the optional C that replaces 2-C 8The cycloalkyl amino group,
R 2, R 3And R 4Represent H independently, halogen, alkyl (1-3C), CF 3, OH, O-alkyl (1-3C), phenoxy group, hydroxyalkyl (1-3C), alkoxyl group (1-2C)-alkyl (1-2C), phenyl, N-(two)-alkyl (1-3C), 1-morpholinyl, piperidino, 1-piperazinyl, OCF 3, SCH 3, SOCH 3, SO 2CH 3, perhaps R 2And R 3Represent the optional cumarone that replaces with the phenyl ring that they connected, Dihydrobenzofuranes, benzodioxan, benzo dioxolane or naphthalene nucleus system,
X represents NH, N-alkyl (1-3C), CH 2, O, S or C-C,
Y represents general formula (A), (B) or group (C):
Figure A0380909300072
Wherein:
R 5Be OH or CH 2OH,
R 6Expression H, alkyl (1-3C), phenyl, NH 2, N-(two)-alkyl (1-3C), OH, O-alkyl (1-3C) or hydroxyalkyl (1-2C),
N is 0,1 or 2,
R 7Expression alkyl (1-3C), benzyl, hydroxyalkyl (1-2C) or methoxyl group alkyl (1-2C),
R 8And R 9Represent H independently, halogen, alkyl (1-3C), CF 3, OH, O-alkyl (1-3C), N-(two)-alkyl (1-3C), 1-morpholinyl, piperidino, 1-piperazinyl, OCF 3, SCH 3, SOCH 3, or SO 2CH 3,
R 10Expression H or alkyl (1-3C),
R 11Expression H, alkyl (1-3C), benzyl, hydroxyalkyl (1-2C) or methoxyl group alkyl (1-2C),
Z represents NOH, NO alkyl (1-3C), O or S.
In described substituent description, abbreviation ' alkyl (1-3C) ' is meant ' methyl, ethyl, n-propyl or sec.-propyl '.
In this manual, ' C 2-C 8Cycloalkyl amino ' be meant any cyclic amine that in ring, contains 2-8 carbon.The cycloalkyl amino ring can contain other atom, and randomly can be substituted.C 2-C 8The example of cycloalkyl amino comprises pyrrolidyl, piperidyl, morpholinyl, aziridinyl, pyrrolinyl etc.
In this manual, ' the optional replacement ' be meant a group can by or can be selected from following one or more groups and further be replaced: alkyl, thiazolinyl; alkynyl, aryl, fluorine; chlorine, bromine, hydroxyl; alkoxyl group, alkene oxygen base, aryloxy; acyloxy, amino, alkylamino; dialkyl amido, arylamino, sulfo-; alkylthio, arylthio, cyano group; oxo, nitro, acyl group; amido, alkyl amido, dialkyl group amido; carboxyl, perhaps two optional substituting groups can form with the carbon atom that they connected and contain 0; 1 or 2 is selected from nitrogen; the heteroatomic 5-of oxygen or sulphur or 6-unit's fragrance or non-aromatic ring.Optional substituting group itself can have additional optional substituting group.The substituting group of preferred optional comprises C 1-3Alkyl such as methyl, ethyl and trifluoromethyl, fluorine, chlorine, bromine, hydroxyl, C 1-3Alkoxyl group such as methoxyl group, oxyethyl group and trifluoromethoxy, and amino.
Wherein the compound that is all formulas (1) of R-configuration or S-configuration of the substituting group on unsymmetrical carbon all belongs to the present invention.
Prodrug, promptly when by any known approach during to people's administration metabolism be the compound of formula (1) compound, also belong to the present invention.Especially, this relates to the compound with primary amino or secondary amino group or hydroxyl, and representative instance is compound and its enantiomorph (seeing below) of formula (9).It can metabolism be the compound of formula (1) compound that such compound can obtain with organic acid reaction.
The present invention be more particularly directed to formula (1) compound, wherein R 1The expression halogen, alkyl (1-3C), O-alkyl (1-3C), CF 3, NH 2Or N-(two)-alkyl (1-3C), and all other symbols have the implication that provides above.
More particularly, the present invention relates to formula (1) compound, wherein R 1=Cl, R 2=H, X=NH, Y are group (A), (B) or (C), and R 6=H, n=1, Z=O, R 10=H and R 3, R 4, R 5, R 7, R 8, R 9And R 11Have the implication that provides above, comprise all possible steric isomer and above-mentioned prodrug, therefore as general formula (2), shown in (3) and (4):
More particularly, the present invention relates to general formula (2), the compound of (3) or (4), wherein R 5=3-CH 2OH; R 7=CH 3R 8=H; R 9=H; R 11=CH 3, and R 3And R 4Have the implication that provides above, comprise all possible steric isomer and above-mentioned prodrug, therefore as general formula (5), shown in (6) and (7):
The more preferably compound of formula (8) and its enantiomorph:
The most preferred embodiment of the present invention is the compound of formula (9) expression:
Figure A0380909300102
This compound has pK i9.0 ± 0.3 to people adenosine-A 3The affinity of acceptor.
The compounds of this invention and salt thereof can obtain according to general routes outlined as described below.R wherein 1Those compounds of=Cl are synthetic according to route 1:
Figure A0380909300103
Route 1
The experimental detail of the first step in this general routes outlined can be referring to following document:
● for X=NH, referring to J.Amer.Chem.Soc.116,1994,4326;
● for the X=N-alkyl, referring to Chem.Pharm.Bull.45,1997,291;
● for X=CH 2, referring to Tetrahedron 56,2000,9705;
● for X=O, referring to Pol.J.Chem.74,2000,837;
● for X=S, referring to J.Chem.Soc.C 1967,466 and
● for the X=C-C, referring to Tetrahedron 56,2000,9705.
R wherein 1The The compounds of this invention of=F or Br can obtain from corresponding three halo derivatives like the complete class.Experimental detail can be referring to following document:
● for R 1Be F, referring to J.Med Chem.36 (26), 4195-4200,1993 and
● for R 1=Br, referring to J.Prakt.Chem.82,536,1910.
R wherein 1=O-alkyl (1-3C) or any amino substituting group: NH 2, N-(two)-alkyl (1-3C), N-(two)-thiazolinyl (1-3C), N-(two)-alkynyl (1-3C), N-alkyl (1-3C) thiazolinyl (1-3C), N-alkyl (1-3C) alkynyl (1-3C), N-thiazolinyl (1-3C) alkynyl (1-3C) or the optional C that replaces 2-C 8The The compounds of this invention of cycloalkyl amino group can be as described in the following route 2, and the further replacement by chlorinated derivative obtains:
Route 2
Experimental detail can be referring to following document:
● for R 1=alkoxyl group, referring to Heterocycles 31 (5), 895-909,1990 and
● for R 1=(replacement) amino, referring to Tetrahedron, 54 (1998) 4051-4065.
R wherein 1=alkyl (1-3C), CF 3Or the The compounds of this invention of iodine can obtain by following route 3 described order synthesis steps.
Route 3
Experimental detail can be referring to following document:
● for R 1=alkyl, referring to J.Med Chem 42 (5), 805-818,1999,
● for R 1=CF 3, referring to J.Chem Soc., Chem Comm 1988, (10) 638-639 and
● for R 1=iodine, referring to Eur.J.Org.Chem., 2002,4181-4184.
Can use standard program well-known in the art, for example, obtain pharmacologically acceptable salt by The compounds of this invention is mixed with suitable acid.
Suitable acid salt can be with mineral acid hydrochloric acid for example, sulfuric acid, and phosphoric acid and nitric acid, or with organic acid citric acid for example, fumaric acid, toxilic acid, tartrate, acetate, trifluoroacetic acid, phenylformic acid, tosic acid, methylsulfonic acid and naphthene sulfonic acid form.
The compound of general formula of the present invention (1) with and salt have adenosine-A 3Antagonism or agonist activity.They can be used for treatment and wherein relate to adenosine-A 3The disease of acceptor perhaps can be by regulating the disease that these acceptors are treated.For example be used for: acute and chronic pain; Struvite disease comprises sacroiliitis, multiple sclerosis, asthma and psoriasis; Stomach-intestines obstacle, as ulcer, inflammatory bowel (crohn) and ulcerative colitis; Anaphylaxis is eczema for example, atopic dermatitis and rhinitis; Cardiovascular diseases is myocardial infarction for example, irregular pulse, hypertension, thrombosis, anaemia, arteriosclerosis, stenocardia; Dermatosis is urticaria for example, lupus erythematosus and itch; Ophthalmic diseases such as glaucoma; Dyspnoea comprises chronic obstructive pulmonary disease, bronchitis and cystic fibrosis; Central nervous system disease comprises various forms of epilepsies, apoplexy, dysthymia disorders, sleep apnea; Impaired with cognitive and memory is the illness alzheimer's disease for example of feature, Ke-Ya syndromes, Huntington Chorea, Parkinson's disease and neural rehabilitation (post-traumatic cerebral lesion); Acute brain or Spinal injury; Diabetes; Osteoporosis; Disease of immune system; Various cancers and leukemia; Bacterium and virus infection.
Adenosine-the A of The compounds of this invention 3Receptor antagonist or exciting character adopt method as described below to measure.
With people adenosine-A 3The receptors bind of acceptor
Described compound and people adenosine-A 3The affinity of acceptor adopts C.A.Salvatore et al.:Molecular cloning and characterization of the human A 3Adenosinereceptor, Proc.Natl.Acad.Sci.USA, 90, 10365-10369, the receptor binding assay described in 1993 is measured.Briefly, from people adenosine-A 3People's reconstitution cell (HEK 293) that acceptor is expressed therein with being stabilized obtains the membrane prepare thing.Not or the concentration of diluting in the damping fluid that is fit to is arranged is in the presence of the test compound of 10 μ M to 0.1nM, with film usefulness [ 125I]-AB-MECA cultivated 90 minutes at 22 ℃.By filtering with Packard GF/B glass fibre filter, use the Packard cell harvestor, with ice-cold damping fluid washing several, carry out separating of binding radioactivity and free radioactivity.(Topcount, Packard), (Microscint 0, Packard) measures binding radioactivity to adopt the liquid scintillation cocktail with scintillometer.The radioactivity of measuring is figure to the test compound concentration of replacing, and calculates the replacement curve, obtain IC by four parameter logistic regressions 50Value, the replacement compound concentrations when promptly 50% radioligand is replaced.Affinity pK IValue is by using radioligand concentration correction IC 50Value is calculated, and it is to people adenosine-A 3The affinity of acceptor is calculated according to the Cheng-Prusoff equation:
pK I＝-log(IC 50/(1+S/K d))
IC wherein 50As mentioned above, S for the test in employed [ 125I]-AB-MECA concentration, represent (being generally 0.1nM) with mol/L, and K dFor [ 125I]-AB-MECA and people adenosine-A 3The balance dissociation constant (0.22nM) of acceptor.
In conjunction with in testing, compound of the present invention has high adenosine-A above-mentioned 3Receptor affinity.This character makes them can be used for treatment wherein to relate to adenosine-A 3The disease of acceptor perhaps can be by regulating the disease that these acceptors are treated.
Embodiment
(1S, 2R)-2-{[4-chloro-6-(3,4-methylenedioxyphenyl base amino)-[1,3,5] triazine-2-yl]-amino }-1-phenyl-third-1-alcohol
Under agitation, in remaining on-20 ℃ the solution of cyanuryl chloride (1.84g) in acetonitrile (20ml), drip 3 in succession, solution and diisopropyl ethyl amine (DIPEA) (1.29g) the solution in acetonitrile (20ml) of 4-methylenedioxyphenyl amine (1.37g) in acetonitrile (20ml).-20 ℃ stir 1 hour after, drip in succession again the solution of DIPEA (1.29g) in acetonitrile (20ml) and (1S, 2R)-(+)-solution of norephedrine (1.51g) in acetonitrile (20ml).Make this mixture be warming up to room temperature naturally, and restir 2 hours.The reaction mixture that vacuum concentration obtains.After adding ethyl acetate (250ml), with organic layer use in succession the HCl aqueous solution (1M, 100ml), the NaOH aqueous solution (1M, 100ml) and salt solution (50ml) wash.The organic layer dried over sodium sulfate is filtered and vacuum concentration.The product that obtains is by purification by silica gel column chromatography, and use heptane: the mixture of ethyl acetate (3: 1) is as elutriant.Obtain pure product (formula (9), referring to top, Embodiment B-44 is referring to table), be white solid, yield is 80%.
Further illustrate the present invention by specific embodiment listed, that represent by following general formula in the following table:
Figure A0380909300141
Wherein Y represents general formula (A), (B) or group (C):
These embodiment only are in order further to illustrate the present invention in more detail, therefore the scope that does not limit the present invention in any way.
Figure A0380909300151
????A-23 ????Cl ????NH ????H ????H ????H ??(A) ??1 ????4-OH ????H
????A-24 ????Cl ????NH ????H ????CH 3 ????H ??(A) ??1 ????4-OH ????H
????A-25 ????Cl ????NH ????Cl ????H ????H ??(A) ??1 ????4-OH ????H
????A-26 ????Cl ????NH ????OCH 3 ????H ????H ??(A) ??1 ????4-OH ????H
????A-27 ????Cl ????NH ????H ????OCH 3 ????H ??(A) ??1 ????4-OH ????H
????A-28 ????Cl ????NH ????OC 2H 5 ????H ????H ??(A) ??1 ????4-OH ????H
????A-29 ????Cl ????NH ????H ????OC 2H 5 ????H ??(A) ??1 ????4-OH ????H
????A-30 ????Cl ????NH ????H ????(CH 2) 2OH ????H ??(A) ??1 ????4-OH ????H
????nr ????R 1 ????X ????R 2 ????R 3 ????R 4 ??Y ??n ????R 5 ????R 6
????A-31 ????Cl ????NH The O-phenyl ????H ????H ??(A) ??1 ????4-OH ????H
????A-32 ????Cl ????NH ????H The O-phenyl ????H ??(A) ??1 ????4-OH ????H
????A-33 ????Cl ????NH ????H The 1-morpholinyl ????H ??(A) ??1 ????4-OH ????H
????A-34 ????Cl ????NH ????CH 3 ????CH 3 ????H ??(A) ??1 ????4-OH ????H
????A-35 ????Cl ????NH ????F ????CH 3 ????H ??(A) ??1 ????4-OH ????H
????A-36 ????Cl ????NH ????F ????OCH 3 ????H ??(A) ??1 ????4-OH ????H
????A-37 ????Cl ????NH ????OCH 3 ????H ????CF 3 ??(A) ??1 ????4-OH ????H
????A-38 ????Cl ????NH ????OCH 3 ????H ????OCH 3 ??(A) ??1 ????4-OH ????H
????A-39 ????Cl ????NH -phenyl- ????H ??(A) ??1 ????4-OH ????H
????A-40 ????Cl ????NH ????????-O-CH 2-O- ????H ??(A) ??1 ????2-CH 2OH ????H
????A-41 ????Cl ????NH ????OCH 3 ????H ????H ??(A) ??1 ????2-CH 2OH ????H
????A-42 ????Cl ????NH ????H ????OCH 3 ????H ??(A) ??1 ????2-CH 2OH ????H
????A-43 ????Cl ????NH ????H ????OC 2H 5 ????H ??(A) ??1 ????2-CH 2OH ????H
????A-44 ????Cl ????NH ????H The 1-morpholinyl ????H ??(A) ??1 ????2-CH 2OH ????H
????A-45 ????Cl ????NH ????CH 3 ????CH 3 ????H ??(A) ??1 ????2-CH 2OH ????H
??A-46 ????Cl ????NH ????F ????OCH 3 ????H ??(A) ??1 ????2-CH 2OH ????H
??A-47 ????Cl ????NH ????OCH 3 ????H ????OCH 3 ??(A) ??1 ????2-CH 2OH ????H
??A-48 ????Cl ????NH ?????????-O-CH 2-O- ????H ??(A) ??1 ????3-CH 2OH ????H
??A-49 ????CH 3 ????NH ?????????-O-CH 2-O- ????H ??(A) ??1 ????3-CH 2OH ????H
??A-50 ????OCH 3 ????NH ?????????-O-CH 2-O- ????H ??(A) ??1 ????3-CH 2OH ????H
??A-51 The 1-morpholinyl ????NH ?????????-O-CH 2-O- ????H ??(A) ??1 ????3-CH 2OH ????H
??A-52 The 1-tetramethyleneimine ????NH ?????????-O-CH 2-O- ????H ??(A) ??1 ????3-CH 2OH ????H
??A-53 The NH-propargyl ????NH ?????????-O-CH 2-O- ????H ??(A) ??1 ????3-CH 2OH ????H
??A-54 ????Cl ????NCH 3 ?????????-O-CH 2-O- ????H ??(A) ??1 ????3-CH 2OH ????H
??A-55 ????Cl ????O ?????????-O-CH 2-O- ????H ??(A) ??1 ????3-CH 2OH ????H
??A-56 ????Cl ????S ?????????-O-CH 2-O- ????H ??(A) ??1 ????3-CH 2OH ????H
??A-57 ????Cl ????CH 2 ?????????-O-CH 2-O- ????H ??(A) ??1 ????3-CH 2OH ????H
??A-58 ????Cl Key ?????????-O-CH 2-O- ????H ??(A) ??1 ????3-CH 2OH ????H
??A-59 ????Cl ????NH ?????????-O-CH 2-O- ????H ??(A) ??1 ????4-CH 2OH ????H
??A-60 ????Cl ????NH ?????????-O-CH 2-O- ????H ??(A) ??0 ????3-OH ????H
??A-61 ????Cl ????NH ????CH 3 ????H ????H ??(A) ??0 ????3-OH ????H
??nr ????R 1 ????X ????R 2 ????R 3 ????R 4 ??Y ??n ????R 5 ????R 6
??A-62 ????Cl ????NH ????Cl ????H ????H ??(A) ??0 ????3-OH ????H
??A-63 ????Cl ????NH ????OCH 3 ????H ????H ??(A) ??0 ????3-OH ????H
??A-64 ????Cl ????NH ????H ????OCH 3 ????H ??(A) ??0 ????3-OH ????H
??A-65 ????Cl ????NH ????H ????OC 2H 5 ????H ??(A) ??0 ????3-OH ????H
??A-66 ????Cl ????NH ????H The 1-morpholinyl ????H ??(A) ??0 ????3-OH ????H
??A-67 ????Cl ????NH ????CH 3 ????CH 3 ????H ??(A) ??0 ????3-OH ????H
??A-68 ????Cl ????NH ????F ????CH 3 ????H ??(A) ??0 ????3-OH ????H
??A-69 ????Cl ????NH ????F ????OCH 3 ????H ??(A) ??0 ????3-OH ????H
??A-70 ????Cl ????NH -phenyl- ????H ??(A) ??0 ????3-OH ????H
??A-71 ????Cl ????NH ????-O-CH 2-O- ????H ??(A) ??0 ????3-CH 2OH ????H
?B-17 ????Cl ????NH ????OCH 2CH 3 ??H ????H ????(B) ????CH 3 ????H ????H ??CH 3 ????1R，2R
?B-18 ????Cl ????NH ????CH 3 ??H ????H ????(B) ????CH 3 ????H ????H ??H ????1S，2R
?B-19 ????Cl ????NH ????Cl ??H ????H ????(B) ????CH 3 ????H ????H ??H ????1S，2R
?B-20 ????Cl ????NH ????Cl ??H ????H ????(B) ????CH 3 ????H ????H ??CH 3 ????1R，2R
?B-21 ????Cl ????NH ????CH(OH)CH 3 ??H ????H ????(B) ????CH 3 ????H ????H ??H ????1S，2R
?B-22 ????Cl ????NH ????CH(OH)CH 3 ??H ????H ????(B) ????CH 3 ????H ????H ??CH 3 ????1R，2R
?B-23 ????Cl ????NH The O-phenyl ??H ????H ????(B) ????CH 3 ????H ????H ??H ????1S，2R
?B-24 ????Cl ????NH The O-phenyl ??H ????H ????(B) ????CH 3 ????H ????H ??CH 3 ????1R，2R
?B-25 ????Cl ????NH ????H ??OCH 3 ????H ????(B) ????CH 3 ????H ????H ??H ????1S，2R
?B-26 ????Cl ????NH ????H ??OCH 3 ????H ????(B) ????CH 3 ????H ????H ??H ????1R，2S
?B-27 ????Cl ????NH ????H ??OCH 3 ????H ????(B) ????CH 3 ????H ????H ??CH 3 ????1R，2R
?B-28 ????Cl ????NH ????H ??OCH 2CH 3 ????H ????(B) ????CH 3 ????H ????H ??H ????1S，2R
?B-29 ????Cl ????NH ????H The 1-morpholinyl ????H ????(B) ????CH 3 ????H ????H ??H ????1S，2R
?B-30 ????Cl ????NH ????H ??CH 3 ????H ????(B) ????CH 3 ????H ????H ??H ????1S，2R
?Nr ????R 1 ????X ????R 2 ??R 3 ????R 4 ????Y ????R 7 ????R 8 ????R 9 ??R 10 Three-dimensional
?B-31 ????Cl ????NH ????H ??CF 3 ????H ????(B) ????CH 3 ????H ????H ??H ????1S，2R
?B-32 ????Cl ????NH ????H The O-phenyl ????H ????(B) ????CH 3 ????H ????H ??H ????1S，2R
?B-33 ????Cl ????NH ????H The O-phenyl ????H ????(B) ????CH 3 ????H ????H ??CH 3 ????1R，2R
?B-34 ????Cl ????NH ????H ????(CH 2) 2OH ????H ????(B) ????CH 3 ????H ????H ??CH 3 ????1R，2R
?B-35 ????Cl ????NH ????F ????CH 3 ????H ????(B) ????CH 3 ????H ????H ??H ????1S，2R
?B-36 ????Cl ????NH ????F ????OCH 3 ????H ????(B) ????CH 3 ????H ????H ??H ????1S，2R
?B-37 ????Cl ????NH ????F ????OCH 3 ????H ????(B) ????CH 3 ????H ????H ??CH 3 ????1R，2R
?B-38 ????Cl ????NH ????F ????OCH 3 ????H ????(B) ????CH 3 ????H ????H ??CH 3 ????1R，2S
?B-39 ????Cl ????NH ????OCH 3 ????H ????CF 3 ????(B) ????CH 3 ????H ????H ??H ????1S，2R
?B-40 ????Cl ????NH ????OCH 3 ????H ????OCH 3 ????(B) ????CH 3 ????H ????H ??H ????1S，2R
?B-41 ????Cl ????NH ????OCH 3 ????H ????OCH 3 ????(B) ????CH 3 ????H ????H ??CH 3 ????1R，2R
?B-42 ????Cl ????NH ????CH 3 ????CH 3 ????H ????(B) ????CH 3 ????H ????H ??H ????1S，2R
?B-43 ????Cl ????NH -phenyl- ????H ????(B) ????CH 3 ????H ????H ??H ????1S，2R
?B-44 ????Cl ????NH ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????H ????H ??H ????1S，2R
?B-45 ????Cl ????NH ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????H ????H ??H ????1R，2S
?B-46 ????Cl ????NH ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????H ????H ??CH 3 ????1S，2R
?B-47 ????Cl ????NH ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????H ????H ??CH 3 ????1S，2S
?B-48 ????Cl ????NH ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????H ????H ??CH 3 ????1R，2S
?B-49 ????Cl ????NH ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????H ????H ??CH 3 ????1R，2R
?B-50 ????Cl ????NCH 3 ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????H ????H ??H ????1S，2R
?B-51 ????Cl ????O ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????H ????H ??H ????1S，2R
?B-52 ????Cl ????S ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????H ????H ??H ????1S，2R
?B-53 ????Cl ????CH 2 ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????H ????H ???H ????1S，2R
?B-54 ????Cl Key ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????H ????H ???H ????1S，2R
?B-55 ????Cl ????NH ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????3-OH ????H ???H ????1R，2S
?B-56 ????Cl ????NH ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????4-OH ????H ???H ????1S，2R
?B-57 ????Cl ????NH ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????3-OH ????4-OH ???H ????1R，2S
?B-58 ????Cl ????NH ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????2-OCH 3 ????5-OCH 3 ???H Racemic
?B-59 ????NH 2 ????NH ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????H ????H ???H ????1R，2S
?B-60 ????N(CH 3) 2 ????NH ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????H ????H ???H ????1R，2S
?B-61 The 1-pyrrolidyl ????NH ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????H ????H ???H ????1S，2R
?Nr ????R 1 ????X ????R 2 ????R 3 ????R 4 ????Y ????R 7 ????R 8 ????R 9 ???R 10 Three-dimensional
?B-62 The 1-morpholinyl ????NH ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????H ????H ???H ????1S，2R
?B-63 Piperidino ????NH ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????H ????H ???H ????1S，2R
?B-64 The NH-propargyl ????NH ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????H ????H ???H ????1S，2R
?B-65 ????N(CH 3) propargyl ????NH ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????H ????H ???H ????1S，2R
?B-66 ????CH 3 ????NH ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????H ????H ???H ????1S，2R
?B-67 ????OCH 3 ????NH ??????-O-CH 2-O- ????H ????(B) ????CH 3 ????H ????H ???H ????1S，2R
Figure A0380909300231
The embodiment of prodrug
The notion of " prodrug " is described for example, has prepared the compound of following formula (10):
Figure A0380909300241
Embodiment The R-group
Preceding-1 Propionyl
Preceding-2 Valeryl
Preceding-3 Nicotinoyl
Preceding-4 N-ethanoyl-different piperidine formyl base
Preceding-5 The methoxyl group ethanoyl
Preceding-6 The acetoxyl group ethanoyl
Preceding-7 Nonanoyl
To the affinity of people's adenosine-A3 acceptor, still after hydrolysis, their do not produce the compound (see above) of the very high formula (9) of activity to the prodrug of formula (10).

Claims (14)

1. the compound of general formula (1), its pharmacologically acceptable salt and wherein the substituting group on potential asymmetric carbon atom be the compound of all formulas (1) of R-configuration or S-configuration, with and prodrug,
Figure A038090930002C1
Wherein
R 1The expression halogen, alkyl (1-3C), O-alkyl (1-3C), CF 3, NH 2, N-(two)-alkyl (1-3C), N-(two)-thiazolinyl (1-3C), N-(two)-alkynyl (1-3C), N-alkyl (1-3C) thiazolinyl (1-3C), N-alkyl (1-3C) alkynyl (1-3C), N-thiazolinyl (1-3C) alkynyl (1-3C) or the optional C that replaces 2-C 8The cycloalkyl amino group,
R 2, R 3And R 4Represent H independently, halogen, alkyl (1-3C), CF 3, OH, O-alkyl (1-3C), phenoxy group, hydroxyalkyl (1-3C), alkoxyl group (1-2C)-alkyl (1-2C), phenyl, N-(two)-alkyl (1-3C), 1-morpholinyl, piperidino, 1-piperazinyl, OCF 3, SCH 3, SOCH 3, SO 2CH 3, perhaps R 2And R 3Represent the optional cumarone that replaces with the phenyl ring that they connected, Dihydrobenzofuranes, benzodioxan, benzo dioxolane or naphthalene nucleus system,
X represents NH, N-alkyl (1-3C), CH 2, O, S or C-C,
Y represents general formula (A), (B) or group (C):
Figure A038090930002C2
Wherein:
R 5Be OH or CH 2OH,
R 6Expression H, alkyl (1-3C), phenyl, NH 2, N-(two)-alkyl (1-3C), OH, O-alkyl (1-3C) or hydroxyalkyl (1-2C),
N is 0,1 or 2,
R 7Expression alkyl (1-3C), benzyl, hydroxyalkyl (1-2C) or methoxyl group alkyl (1-2C),
R 8And R 9Represent H independently, halogen, alkyl (1-3C), CF 3, OH, O-alkyl (1-3C), N-(two)-alkyl (1-3C), 1-morpholinyl, piperidino, 1-piperazinyl, OCF 3, SCH 3, SOCH 3, or SO 2CH 3,
R 10Expression H or alkyl (1-3C),
R 11Expression H, alkyl (1-3C), benzyl, hydroxyalkyl (1-2C) or methoxyl group alkyl (1-2C),
Z represents NOH, NO alkyl (1-3C), O or S.
2. the compound of the described general formula of claim 1 (1), wherein R 1The expression halogen, alkyl (1-3C), O-alkyl (1-3C), CF 3, NH 2Or N-(two)-alkyl (1-3C); R 2, R 3And R 4Represent H independently, halogen, alkyl (1-3C), CF 3, OH, O-alkyl (1-3C), phenyl, N-(two)-alkyl (1-3C), 1-morpholinyl, piperidino, 1-piperazinyl, OCF 3, SCH 3, SOCH 3, SO 2CH 3, perhaps R 2And R 3Represent cumarone with the phenyl ring that they connected, benzodioxan or benzo dioxolane ring system, X represents NH, N-alkyl (1-3C), CH 2, O, S or C-C, Y represent general formula (A) or group (B), wherein R 5Be OH or CH 2OH; R 6Expression H, alkyl (1-3C), phenyl, NH 2, N-(two)-alkyl (1-3C), OH, O-alkyl (1-3C) or hydroxyalkyl (1-2C); N is 0,1 or 2; R 7Expression alkyl (1-3C), benzyl or hydroxyalkyl (1-2C); R 8And R 9Represent H independently, halogen, alkyl (1-3C), CF 3, OH, O-alkyl (1-3C), N-(two)-alkyl (1-3C), 1-morpholinyl, piperidino, 1-piperazinyl, OCF 3, SCH 3, SOCH 3, or SO 2CH 3And R 10=H.
3. the compound of the described general formula of claim 1 (1), wherein Y is the group of general formula (A), and R 1, R 2, R 3, R 4, R 5, R 6, X and n have the implication described in the claim 1.
4. the compound of the described general formula of claim 1 (1), wherein Y is the group of general formula (A), and R 1, R 2, R 3, R 4, R 5, R 6, X and n have the implication described in the claim 2.
5. the compound of the described general formula of claim 1 (1), wherein Y is the group of general formula (B), and R 1, R 2, R 3, R 4, R 7, R 8, R 9, R 10Has the implication described in the claim 1 with X.
6. the compound of the described general formula of claim 1 (1), wherein Y is the group of general formula (B), and R 1, R 2, R 3, R 4, R 7, R 8, R 9, R 10Has the implication described in the claim 2 with X.
7. the compound of the described general formula of claim 1 (1), wherein Y is the group of general formula (C), and R 1, R 2, R 3, R 4, R 8, R 9, R 10, R 11, X and Z have the implication described in the claim 1.
8. the compound of the described general formula of claim 1 (1), wherein R 1=Cl, R 2=H, X=NH, Y are group (A), (B) or (C), and R 6=H, n=1, Z=O, R 10=H, and R 3, R 4, R 5, R 7, R 8, R 9And R 11Has the implication described in the claim 1.
9. the compound of the described general formula of claim 1 (1), wherein R 1=Cl, R 2=H, X=NH, Y are group (A), (B) or (C), and R 5=3-CH 2OH, R 6=H, n=1, R 7=CH 3R 8=H; R 9=H, Z=O, R 10=H, R 11=CH 3, and R 3And R 4Has the implication described in the claim 1.
10. described compound and the enantiomorph thereof of claim 1 with general formula (8):
Figure A038090930004C1
11. the described compound of claim 1 with general formula (9)
12. pharmaceutical composition, contain pharmacological activity amount, among at least a claim 1-11 any described compound as activeconstituents.
13. any described compound is used for the treatment of in preparation and wherein relates to adenosine-A among the claim 1-11 3The disease of acceptor or can be by the purposes in the pharmaceutical composition of regulating the disease that these acceptors treat.
14. the described purposes of claim 13, wherein said disease are acute and chronic pain; Struvite disease comprises sacroiliitis, multiple sclerosis, asthma and psoriasis; Stomach-intestines obstacle, as ulcer, inflammatory bowel (crohn) and ulcerative colitis; Anaphylaxis is eczema for example, atopic dermatitis and rhinitis; Cardiovascular diseases is myocardial infarction for example, irregular pulse, hypertension, thrombosis, anaemia, arteriosclerosis, stenocardia; Dermatosis is urticaria for example, lupus erythematosus and itch; Ophthalmic diseases such as glaucoma; Dyspnoea comprises chronic obstructive pulmonary disease, bronchitis and cystic fibrosis; Central nervous system disease comprises various forms of epilepsies, apoplexy, dysthymia disorders, sleep apnea; Impaired with cognitive and memory is the obstacle alzheimer's disease for example of feature, Ke-Ya syndromes, Huntington Chorea, Parkinson's disease and neural rehabilitation (post-traumatic cerebral lesion); Acute brain or Spinal injury; Diabetes; Osteoporosis; Disease of immune system; Various cancers and leukemia; Bacterium and virus infection.
CNB038090937A 2002-05-30 2003-05-28 1,3,5-triazine derivatives as ligands for human adenosine-A3 receptors Expired - Fee Related CN1329388C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02077310 2002-05-30
EP02077310.7 2002-05-30

Publications (2)

Publication Number Publication Date
CN1646520A true CN1646520A (en) 2005-07-27
CN1329388C CN1329388C (en) 2007-08-01

Family

ID=29595045

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038090937A Expired - Fee Related CN1329388C (en) 2002-05-30 2003-05-28 1,3,5-triazine derivatives as ligands for human adenosine-A3 receptors

Country Status (16)

Country Link
EP (1) EP1513827A1 (en)
JP (1) JP4590260B2 (en)
CN (1) CN1329388C (en)
AR (1) AR040231A1 (en)
AU (1) AU2003250232B2 (en)
BR (1) BR0304925A (en)
CA (1) CA2484981C (en)
HK (1) HK1075045A1 (en)
HR (1) HRP20040970A2 (en)
IL (1) IL164240A (en)
MX (1) MXPA04011948A (en)
PL (1) PL372418A1 (en)
RU (1) RU2312859C2 (en)
UA (1) UA77816C2 (en)
WO (1) WO2003101980A1 (en)
ZA (1) ZA200408029B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2533397A1 (en) * 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
ES2665561T3 (en) 2012-07-04 2018-04-26 Agro-Kanesho Co., Ltd. Ester derivative of 2-aminonicotinic acid and bactericide containing the same as active ingredient
GB201810668D0 (en) 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226735D0 (en) * 1992-12-22 1993-02-17 Ici Plc Azole derivatives
DE19735800A1 (en) * 1997-08-18 1999-02-25 Boehringer Ingelheim Pharma Use of known and new triazine derivatives
JPH11158073A (en) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd Adenosine a3 antagonist

Also Published As

Publication number Publication date
AR040231A1 (en) 2005-03-23
AU2003250232A1 (en) 2003-12-19
JP2005531600A (en) 2005-10-20
IL164240A (en) 2010-12-30
AU2003250232B2 (en) 2008-09-11
CA2484981A1 (en) 2003-12-11
ZA200408029B (en) 2005-10-06
UA77816C2 (en) 2007-01-15
PL372418A1 (en) 2005-07-25
CA2484981C (en) 2011-07-26
WO2003101980A1 (en) 2003-12-11
RU2004138803A (en) 2005-06-10
RU2312859C2 (en) 2007-12-20
EP1513827A1 (en) 2005-03-16
MXPA04011948A (en) 2005-03-31
CN1329388C (en) 2007-08-01
BR0304925A (en) 2004-09-28
JP4590260B2 (en) 2010-12-01
HRP20040970A2 (en) 2005-06-30
IL164240A0 (en) 2005-12-18
HK1075045A1 (en) 2005-12-02

Similar Documents

Publication Publication Date Title
CN1157386C (en) Trisubstituted 1,3,5-triazine derivatives for treatment by HIV infections
CN1195755C (en) Pyrrolo [2,3-d] pyrimidine compounds
JP5847087B2 (en) Fused heterocyclic compounds as orexin receptor modulators
CN1227237C (en) Piperazinylpyrazines compounds as antagonists of serotonin-5-HT2 receptor
CN1149873A (en) Piperazine derivatives as 5HT1A antagonists
CN1681774A (en) Processes for the preparation of 4- 4- 4-(2 -cyanoethenyl)-2,6-dimethylphenyl )amino) -2-pyrimidinyl)amino benzonitrile
WO2013005755A1 (en) Methylpiperidine derivative
CN1039491C (en) Compounds
JP2012529536A (en) Benzimidazole derivatives useful as TRPM8 channel modulators
CN1160360C (en) Benzoxazine compounds for enhancing synaptic response
CN1646520A (en) 1,3,5-triazine derivatives as ligands for human adenosine-A3 receptors
US7307079B2 (en) 1,3,5-Triazine derivatives as ligands for human adenosine-A3 receptors
CN1054844C (en) N-substituted azabicycloheptane derivatives their preparation and use
CN1314674C (en) Use of 2-amino-thiazoline derivatives as inhibitors of inducible NO-synthase
CN100341854C (en) Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
JP2014141480A (en) Pharmaceuticals containing methylpiperidine derivatives
CN1156454A (en) N-substituted 3-azabicyclo(3,2,0) heptane derivatives and preparing method and use thereof
CN1043574C (en) Heterocyclic amines having central nervous system activity
CN1255131A (en) Amidine derivatives as inhibitors of nitric oxide synthase
CN1582275A (en) Calcium antagonistic compound
CN1838951A (en) Bicycl 3.1.1]heptane substituted benzimidazolone and quinazolinone derivatives as agonists on human orl1 receptors
CN1077890C (en) 4-aminoethyoxy-indolone derivatives as dopamine D2 agonists
CN1304409A (en) Indol-3-Yl-cyclohexyl amide derivatives for treatment of depression (5-HT1 receptor antagonists)
CN1040756C (en) heterocyclic compounds
RU2005130647A (en) NEW AMINOPYRIDINE DERIVATIVES AS mGIuR5 ANTAGONISTS

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1075045

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070801

Termination date: 20120528